Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. Knowledge, attitudes and policies regarding medical cannabis and cannabis-based drugs are changing. Here are the takeaways ( Source Fitch). Source: [link].

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

NOVEMBER 20, 2023

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. THC is the primary psychoactive compound in cannabis, responsible for the “high” or euphoric feeling associated with marijuana use.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

MGC Pharma

NOVEMBER 1, 2017

This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence: MGC Pharmaceuticals has just released their first product to the market. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Medicine CBD 100

Cannabis Law Report

JULY 6, 2021

The Tasmanian Advocate Reports… Tasmanian hospitals and Ambulance Tasmania might not use medicinal cannabis often, or at all, any time soon, despite a new supply agreement. It appears most likely to be used for small children with severe myoclonic epilepsy, known as Dravet syndrome.

Medicine 105

Medicine Epilepsy Pharmaceutical Access 105

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. The Georgia State Board of Pharmacy recently made the decision to endorse more cannabis oil sale outlets. Its conversion into low-THC cannabis oil also allowed for treating many diseases.

Oil 97

Oil Patients Access THC 97

Cannabis Law Report

JULY 2, 2021

Chulalongkorn University has established the “Chula Cannabis and its Natural Substances (Chula C.A.N.S.) Rungpetch Sakulbumrungsilp Dean of the Faculty of Pharmaceutical Sciences, Chulalongkorn University. very little research on cannabis has been carried out during the 10 years before its legalization. According to Asst.

Research and Development 105

Research and Development Pharmaceutical Extraction Seed-To-Sale 105

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JULY 7, 2022

Eleven of thirteen cannabis patent claims survive PTAB challenge. filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. GW Pharma Limited and Otsuka Pharmaceutical Co.,

Epilepsy 52

Epilepsy Pharmaceutical Treatment Cannabinoids 52

Cannabis Law Report

NOVEMBER 5, 2019

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. based on its latest 2019Q2 regulatory filing with the SEC.

Pharmaceutical 45

Pharmaceutical Epilepsy Treatment Medicine 45

Cannabis Law Report

JANUARY 16, 2022

The government will review the Dangerous Drugs Act 1952 and the Poisons Act 1952 to regulate cannabis and ketum for medical use, Health Minister Khairy Jamaluddin said. Cannabis, or marijuana, is currently banned under the Dangerous Drugs Act that imposes extremely harsh penalties for the use of illegal narcotics.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

OCTOBER 5, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Leafwell

MAY 5, 2021

When it comes to caring for diseases and the most vulnerable among us, there are some clear areas where modern pharmaceutical medicine fails, and where medical marijuana succeeds.

Chronic Pain 52

Chronic Pain Epilepsy Law Pharmaceutical 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

The Cannigma

JUNE 1, 2021

While France has long been said to have the highest number of cannabis users per capita in Europe, it has long lagged behind its western Europe neighbors when it comes to tolerance of the plant. Marijuana is not legal in France, and the country is seen as having some of the strictest cannabis policies in western Europe. Shutterstock.

Law 113

Law Epilepsy Programs Patients 113

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Epidiolex is sourced from natural cannabis grown by the British drugmaker in the United Kingdom.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. A Cannabis plant is made up of 400 different chemicals that have physical and psychoactive effects when consumed together. Cannabinoids Many of the components found in Cannabis plants are known as cannabinoids. You can learn more about it here.

Epilepsy 100

Epilepsy Cannabinoids Pharmaceutical THC 100

Cannabis Law Report

JULY 24, 2019

Dr Mikael Sodergren , Managing Director and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

SEPTEMBER 14, 2021

Depending on who you’re talking to, the plant is either an illegal and addictive narcotic, or a source of miracle treatments for everything from epilepsy, to back pain; there even some who claim it can help with depression. 33mins 24secs Is medical cannabis a wonder drug hiding in plain sight? LISTEN [link].

Medicine 52

Medicine Epilepsy Pharmaceutical History 52

United Patients Group

APRIL 18, 2023

Introduction The medical cannabis industry is booming. However, there are still many myths about cannabis that persist despite being debunked by medical professionals and researchers alike. Myth: Cannabis is just a drug. Cannabis is a plant. Myth: Cannabis is a gateway to other drugs. Myth: Cannabis is a cure-all.

Research and Development 108

Research and Development Indica Treatment Conditions 108

The Fresh Toast

MARCH 5, 2020

In patients with rare forms of epilepsy, artisanal CBD increased seizures while pharmaceutical CBD caused seizure reduction. Continue reading You Should Reconsider Using Store-Bought CBD To Treat Seizures at The Fresh Toast.

CBD 52

CBD Epilepsy Pharmaceutical Patients 52

Veriheal

AUGUST 2, 2023

That’s right; cannabis could be very beneficial in your mission to remain mindful while parenting. Let’s explore five reasons why many parents are choosing to utilize cannabis as a tool in their parenting repository. Cannabis can be a helpful tool for mindful parenting when you want to let loose a little.

Microdosing 94

Microdosing Consumption Pharmaceutical Cannabis 94